Literature DB >> 30722755

New opportunities to optimize antithrombotic therapy for secondary stroke prevention.

Anthony S Kim1, J Donald Easton1.   

Abstract

Stroke symptoms can be unsettling, even when symptoms resolve, but focusing on stroke prevention can be empowering provided that effective interventions for appropriate patient populations are available. Current options include interventions for symptomatic carotid artery stenosis, anticoagulation for atrial fibrillation, high-dose statins, new oral anticoagulants, new developments in atrial fibrillation detection, and new therapeutics are in development. For antiplatelet therapy, aspirin monotherapy is effective but dual antiplatelet therapy with the combination of aspirin and clopidogrel increases hemorrhage risks over the long term that outweigh potential benefits. In the short term though, both the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials have shown a benefit of short-term dual-antiplatelet therapy, though the increased major hemorrhage risk seen in POINT could justify applying dual-antiplatelet therapy to just the first 21 days. Furthermore, since clopidogrel is a prodrug that must be metabolized to have antiplatelet activity, it is not surprising that the treatment effect in CHANCE was limited to patients who were not carriers of loss-of-function alleles for clopidogrel metabolism. Ticagrelor, an antiplatelet agent which failed to meet its primary endpoint as monotherapy compared to aspirin in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial, is currently being tested as combination therapy with aspirin compared to aspirin alone in Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES). These developments along with improvements to the infrastructure to perform rapid evaluations and to apply intensive secondary stroke prevention interventions hold continued promise for the future.

Entities:  

Keywords:  Stroke prevention; antiplatelet; antithrombotic; aspirin; clopidogrel; secondary stroke prevention; ticagrelor; transient ischemic attack

Mesh:

Substances:

Year:  2019        PMID: 30722755     DOI: 10.1177/1747493019828548

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  3 in total

Review 1.  Carotid Atherosclerosis in Patients with Atrial Fibrillation.

Authors:  Zhaojia Wang; Panagiotis Korantzopoulos; Tong Liu
Journal:  Curr Atheroscler Rep       Date:  2019-11-29       Impact factor: 5.113

Review 2.  Oxidative Injury in Ischemic Stroke: A Focus on NADPH Oxidase 4.

Authors:  Ganglei Li; Changsheng Ye; Yu Zhu; Tiesong Zhang; Jun Gu; Jianwei Pan; Feng Wang; Fan Wu; Kaiyuan Huang; Kangli Xu; Xiaomin Wu; Jian Shen
Journal:  Oxid Med Cell Longev       Date:  2022-02-03       Impact factor: 6.543

3.  Atrial Fibrillation and Stroke Symptoms in the REGARDS Study.

Authors:  Meghan Reading Turchioe; Elsayed Z Soliman; Parag Goyal; Alexander E Merkler; Hooman Kamel; Mary Cushman; Orysya Soroka; Ruth Masterson Creber; Monika M Safford
Journal:  J Am Heart Assoc       Date:  2022-01-13       Impact factor: 6.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.